Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Status:
Terminated
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of pyrotinib in combination with
nab-paclitaxel or trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or
locally advanced HER2-positive breast cancer.